Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the RSV immune response.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518191-31-00

Acronym

RSV-REUMA

Enrollment

180

Registered

2025-07-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory rheumatic disease

Brief summary

Antibody response, i.e. fold-change of RSVpreF-specific IgG antibody level from pre- to post-vaccination (3-6 weeks).

Detailed description

Functional RSVpreF-antigen specific T-cell response., Reported adverse events.

Interventions

DRUGArexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant

DRUGadjuvanted)

DRUGAbrysvo powder and solvent for solution for injection Respiratory syncytial virus vaccine (bivalent

DRUGrecombinant)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Antibody response, i.e. fold-change of RSVpreF-specific IgG antibody level from pre- to post-vaccination (3-6 weeks).	—

Secondary

Measure	Time frame
Functional RSVpreF-antigen specific T-cell response., Reported adverse events.	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026